App-Quantinova.ai

Reshaping immune lung populations to inhibit pulmonary fibrosis and cancer by activation of purinergic receptor P2RX7

Serena Janho dit Hreich - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

FK506-binding protein 11, a novel plasma cell specific antibody folding catalyst, is increased in idiopathic pulmonary fibrosis

Stefan Preisendörfer - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Tacrolimus

Degeneration of nerve fibers in chronic obstructive lung disease and usual interstitial pneumonia

Johannes Leopold - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Acetylcholine

What cells are replacing the epithelium in cystic remodeling in UIP and COPD

Florian Gallob - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Uteroglobin

Extracellular matrix biomarkers predict change in lung function in idiopathic pulmonary fibrosis

Henrik Jessen - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

IL-18 binding protein as a noble biomarker for idiopathic pulmonary fibrosis

Yu Nakanisihi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

IL-18BP

Associations of serological markers of sICAM-1, IL-1ß, MIF and su-PAR with 3-month mortality in acute exacerbation of Idiopathic Pulmonary Fibrosis

Xuran Li - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

sICAM-1

Extracellular HSP90a promotes cellular senescence in pulmonary fibrosis through TGFß signaling

Hangming Dong - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

Immunological profiling of chronic obstructive airways disease and idiopathic pulmonary fibrosis

Jacobo Sellares Torres - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial

Manuela Funke-Chambour - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Azithromycin

Impaired cerebral oxygenation: a cause for exercise intolerance in patients with fibrotic interstitial lung disease?

Mathieu Marillier - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Energy cost of walking : Idiopathic Pulmonary Fibrosis vs COPD

Khadija Ayed - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis

Philippe Bonniaud - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Management-related costs of Idiopathic Pulmonary Fibrosis (IPF in Belgium

Danielle Strens - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: A population-based case-control study

Misbah Baqir - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Evaluation of cardiac function by echocardiography in patients with interstitial lung disease, divided by ILD group

Valeria Ariadna Martínez Vázquez - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis

Erik Palmer - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Six-Minute Walk Test in Interstitial Lung Disease : various outcomes for various causes

Khadija Ayed - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Idiopathic pulmonary fibrosis and systemic sclerosis-interstitial lung disease: features at admission to a tertiary pulmonology unit

Serena Vettori - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Relationship between horizontal adductor muscles strength and pulmonary functions in idiopathic pulmonary fibrosis

Habibe Durdu - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Filters

914 Abstracts